Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms
Literature
Read More
A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer
Literature
Read More
Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy
Literature
Read More
Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease and recurrence in patients with head and neck squamous cell carcinoma
Literature
Read More
Real time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC
Literature
Read More
Talking Cancer: Conversations with Trailblazers, Advocates, Patients, and Medical Ambassadors
Blog
Read More
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR™ MRD and InVisionFirst®-Lung Assays at the ESMO Congress 2021
Press Release
Read More